production of the hormone ill. Study of the -. by determining the time for a 5696-reduction from the peak increment of the sterol. In normal Methods subjects the calculated value ranged from 5 to 8 h compared with 18 to 44 h in uraemic patients.
Measurement of 1,25-(0H),D,
1,25-(OH),D, was measured by radioimmunoassay [21 with the following modifications. Serum (5 ml) was extracted with an equal volume of cyclohexane/ethyl acetate (1: 1, v/v). Extracts were purified by Sephadex LH20 followed by high pressure liquid chromatography (HPLC). 1,25-(OH),D, fractions were assayed with antiserum 02282 at a final dilution of 1 : 1OOOOO in a phosphate buffer (KH,PO,, 70 mmol; pH 6.0). The tracer used was [23,24-3Hl-1,25-(OH),D3 with a specific radioactivity of 7&110 Ci/mmol (Amersham International). The sensitivity of the assay was 10 fmolhube, resulting in a detection limit of 19 pmolh when 5 ml of serum was extracted. The normal range of the assay is 53-142 pmolh (n = 34).
Administration of I ,25-(0H)p3
Four normal male subjects aged between 25
and 32 years, and six patients with chronic renal 
Results
The increase in circulating concentrations of 1,25-dihydroxycholecallciferol achieved in four normal and six uraemic subjects after an oral dose of 2 pg is illustrated in Fig. 1 . In the normal individuals the pattern was characterized by rapid absorption, with 1,25-(OH),D3 concentrations reaching a peak at between 1 and 7 h. The range in the peak increment over basal values was 123-257 pmol/l and the absolute peak concentration achieved was between 235 and 35 1 pmol/l. Thereafter, concentrations fell 300 la) Normal progressively and were 12-26 pmol/l above basal values at 24 h. Fig. 1 also depicts the increase in circulating 1,25-(OH),D, in six uraemic subjects after a 2 pg oral dose. In three of these subjects, the basal concentration was undetectable (< 19 pmol/l) and, in the remainder, it was at the limit of detection. 1,25-(OH),D, appeared rapidly in serum from uraemic patients after the dose, with the pattern for absorption being similar to that observed in normal subjects. Absolute peak concentrations of 108-212 pmol/l were reached 3-7 h after administration of the sterol. However, in contrast with the rapid disappearance of 1,25-(OH),D, from the blood of normal subjects, the clearance in uraemic patients was delayed. At 24 h the concentration was from 60 to 91 pmol/l above basal.
The half-time of the disappearance of orally administered 1,25-(OH),D3 from the circulation was estimated by determining the time taken for a 50% reduction from peak increment of the sterol. By this evaluation, the calculated half-times for normal subjects ranged from 5 to 8 h and half-times for the uraemic patients were from 18 to 44 h. The peak increment in 1,25-(OH),D, after the oral dose did not differ significantly between the normal subjects and the patients with chronic renal failure. However, the value at 24 h Although the increase in circulating 1,25-(OH),D, in uraemic patients was similar to that observed in normal subjects, the disappearance of the sterol from their circulation was clearly delayed. It might be argued that the deficiency in 1,25-(OH),D, in uraemic patients before treatment could have affected the distribution of the exogenous sterol, thus in part accounting for the observed delayed clearance. However, for comparison, we studied a patient with untreated hypoparathyroidism who had unmeasurable concentrations of 1,25-(OH),D, before the oral dose and the pattern seen was similar to that in healthy 5-8 h.
subjects . In this patient, the 1,25-(OH) ,D, concentration rose from 24 pmol/l to reach a peak of 240 pmol/l by 7 h and fell to an undetectable concentration by 24 h. 1,25-(OH),D3 is further metabolized, for example, to 1,24,25-trihydroxy-vitamin D [8] and to calcitroic acid, which has a carboxylic acid group in the side chain at position C-23. Although the full role of the kidney in the further metabolism of 1,25-(OH),D, remains to be established, it would seem possible from the studies presented here that this organ is not only the site of synthesis of 1,25-(OH),D,, but may also be important in the metabolism of the sterol and its removal from the circulation. In addition, delayed clearance of 1,25-(OH),D3 used in the treatment of renal osteodystrophy may be a factor in the development of hypercalcaemia in uraemic patients and necessitate a reduction in the dosage required.
